Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: A useful cutoff in clinical practice

American Journal of Gastroenterology

Volumn 110, Issue 3, 2015, Pages 472-473

  Bodini, Giorgia ^a   Giannini, Edoardo G ^a   Savarino, Edoardo V ^b   Savarino, Vincenzo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

CLINICAL ARTICLE; CLINICAL PRACTICE; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; INFLAMMATORY BOWEL DISEASE; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE; ALGORITHM; FEMALE; INFLAMMATORY BOWEL DISEASES; MALE;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE;

EID: 84924301884     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.10     Document Type: Letter

References (3)

1. Roblin X , Rinaudo M , Del Tedesco E et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in infl ammatory bowel diseases . Am J Gastroenterol 2014 ; 109 : 1250-6
2. Roblin X , Marotte H , Rinaudo M et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with infl ammatory bowel diseases . Clin Gastroenterol Hepatol 2014 ; 1 : 80-4
3. Roblin X , Rinaudo M , Sparrow MP et al. Pharmacokinetics in IBD: Ready for prime time?. Curr Drug Targets 2014 ; 15 : 1049-55